Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine

Xueyang Jiang,Chang Liu,Manxing Zou,Huanfang Xie,Tailiang Lin,Weiping Lyu,Jian Xu,Yuan Li,Feng Feng,Haopeng Sun,Wenyuan Liu

DOI: https://doi.org/10.1016/j.ejmech.2021.113663

IF: 7.088

2021-11-01

European Journal of Medicinal Chemistry

Abstract:<p>Acetylcholinesterase (AChE) inhibitors are currently the first-line drugs approved by the FDA for the treatment of Alzheimer's disease (AD). However, a short effective-window limits their therapeutic benefits. Clinical studies have confirmed that the combination of AChE inhibitors and neuroprotective agents exhibits better anti-AD effects. We have previously reported that the dual AChE/GSK3β (Glycogen synthase kinase 3β) modulators have both neuroprotective effects and cognitive impairment-improvement effects. In this study, we characterized a new backbone of the AChE/GSK3β inhibitor <strong>11c</strong>. It was identified as a highly potent AChE inhibitor and was found superior to donepezil, the first-line drug for the treatment of AD. <em>In vivo</em> studies confirmed that <strong>11c</strong> significantly inhibited the activity of AChE in the brain but had little effect on the activity of AChE in the intestine. This advantage of <strong>11c</strong> was expected to reduce the peripheral side effects caused by donepezil. Furthermore, biomarker studies have shown that <strong>11c</strong> also improved the levels of acetylcholine and synaptophysin in the brain and exhibited neuroprotective effects. Preliminary <em>in vivo</em> and <em>in vitro</em> research results underline the exciting potential of compound <strong>11c</strong> in the treatment of AD.</p>

chemistry, medicinal